PriceTargets.com logo

Mereo BioPharma Group - MREO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.50
  • Forecasted Upside: 72.81%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 1 Strong Buy Ratings
$4.34 As of 10/11/2024 01:00 AM ET
▲ +0.22 (5.34%)

This chart shows the closing price for MREO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Mereo BioPharma Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MREO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MREO

Analyst Price Target is $7.50
▲ +72.81% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Mereo BioPharma Group in the last 3 months. The average price target is $7.50, with a high forecast of $8.00 and a low forecast of $7.00. The average price target represents a 72.81% upside from the last price of $4.34.

This chart shows the closing price for MREO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in Mereo BioPharma Group. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/21/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/20/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/18/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/16/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/15/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/14/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/12/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/12/2024

Latest Recommendations

  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/1/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$7.00 ➝ $7.00
9/16/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$7.00 ➝ $7.00
8/13/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
7/22/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$7.00 ➝ $7.00
6/20/2024Leerink PartnersBoost TargetOutperform ➝ Outperform$6.00 ➝ $8.00
6/13/2024Baird R WUpgradeStrong-Buy
6/13/2024Robert W. BairdInitiated CoverageOutperform$8.00
6/12/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$7.00 ➝ $7.00
6/12/2024Needham & Company LLCBoost TargetBuy ➝ Buy$6.00 ➝ $7.00
5/16/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$7.00
5/16/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$6.00
4/10/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$6.00
3/28/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$7.00
3/28/2024Needham & Company LLCBoost TargetBuy ➝ Buy$5.00 ➝ $6.00
3/22/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$7.00
9/8/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$5.00
9/8/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$4.00
8/23/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$5.00
4/21/2023Needham & Company LLCReiterated RatingBuy$5.00
3/30/2023Needham & Company LLCReiterated RatingBuy$5.00
11/10/2022Leerink PartnersLower TargetOutperform$8.00 ➝ $4.00
8/12/2022Cantor FitzgeraldInitiated CoverageOverweight$4.00
6/6/2022Needham & Company LLCLower TargetBuy$10.00 ➝ $5.00
5/13/2022BTIG ResearchReiterated RatingBuy$8.00
4/1/2022Leerink PartnersReiterated RatingBuy$8.00
2/17/2022Leerink PartnersReiterated RatingOutperform
12/13/2021Needham & Company LLCReiterated RatingBuy$10.00
5/5/2021BTIG ResearchInitiated CoverageBuy$10.00
4/5/2021Needham & Company LLCInitiated CoverageBuy$10.00
(Data available from 10/12/2019 forward)

News Sentiment Rating

1.02 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/16/2024
  • 0 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/15/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/15/2024
  • 7 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/14/2024
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/14/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/13/2024
  • 3 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/12/2024
  • 10 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/12/2024

Current Sentiment

  • 10 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Mereo BioPharma Group logo
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $4.34
Low: $4.07
High: $4.34

50 Day Range

MA: $4.28
Low: $3.66
High: $4.87

52 Week Range

Now: $4.34
Low: $3.64
High: $5.02

Volume

552,383 shs

Average Volume

858,690 shs

Market Capitalization

$608.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88

Frequently Asked Questions

What sell-side analysts currently cover shares of Mereo BioPharma Group?

The following Wall Street research analysts have issued stock ratings on Mereo BioPharma Group in the last year: Baird R W, Cantor Fitzgerald, Leerink Partners, Needham & Company LLC, and Robert W. Baird.
View the latest analyst ratings for MREO.

What is the current price target for Mereo BioPharma Group?

4 Wall Street analysts have set twelve-month price targets for Mereo BioPharma Group in the last year. Their average twelve-month price target is $7.50, suggesting a possible upside of 72.8%. Robert W. Baird has the highest price target set, predicting MREO will reach $8.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $7.00 for Mereo BioPharma Group in the next year.
View the latest price targets for MREO.

What is the current consensus analyst rating for Mereo BioPharma Group?

Mereo BioPharma Group currently has 4 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MREO will outperform the market and that investors should add to their positions of Mereo BioPharma Group.
View the latest ratings for MREO.

What other companies compete with Mereo BioPharma Group?

Other companies that are similar to Mereo BioPharma Group include Catalyst Pharmaceuticals, Janux Therapeutics, CG Oncology, Agios Pharmaceuticals and Amphastar Pharmaceuticals. Learn More about companies similar to Mereo BioPharma Group.

How do I contact Mereo BioPharma Group's investor relations team?

Mereo BioPharma Group's physical mailing address is ONE CAVENDISH PLACE FOURTH FLOOR, LONDON X0, W1G0QF. The company's listed phone number is 44-33-3023-7300 and its investor relations email address is [email protected]. The official website for Mereo BioPharma Group is www.mereobiopharma.com. Learn More about contacing Mereo BioPharma Group investor relations.